References:
1. Kraemer KH, DiGiovanna JJ, Tamura D. Xeroderma Pigmentosum
[Internet]. GeneReviews® [Internet]. University of Washington,
Seattle; 2022 [cited 2022 May 14]. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK1397/
2. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, et
al. Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D
Polymorphisms with Response, Toxicity, and Survival in
Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer
Patients. J Thorac Oncol. 2011 Dec 1;6(12):2018–26.
3. Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell
Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin
Dermatol. 2016 Oct;17(5):491–508.
4. Kaloga M, Dioussé P, Diatta BA, Bammo M, Kourouma S, Diabate A, et
al. Squamous Cell Carcinoma in African Children with Xeroderma
Pigmentosum: Three Case Reports. Case Rep Dermatol. 2016;8(3):311–8.
5. Nair AG, Kaliki S, Mishra DK, Reddy VA, Naik MN. Neoadjuvant
chemotherapy for invasive squamous cell carcinoma of the conjunctiva: A
case report. Indian J Ophthalmol. 2015 Dec;63(12):927–9.
6. Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, et
al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the
aged. Am J Clin Oncol. 2000 Apr;23(2):181–4.
7. Denic S. Preoperative treatment of advanced skin carcinoma with
cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32–4.
8. DeConti RC. Chemotherapy of squamous cell carcinoma of the skin.
Semin Oncol. 2012 Apr;39(2):145–9.
9. Sumiyoshi M, Soda H, Sadanaga N, Taniguchi H, Ikeda T, Maruta H, et
al. Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer
Patients with Xeroderma Pigmentosum. Intern Med. 2017 Apr
15;56(8):979–82.
10. Carneiro MC, Kimura T de C, Tolentino E de S, Pieralisi N, Veltrini
VC. Unusual intraoral cancer with unexpected outcome in a patient with
xeroderma pigmentosum: An alert for antineoplastic treatment. Oral Surg
Oral Med Oral Pathol Oral Radiol. 2020 Jan 1;129(1):e1–11.
11. Gilbar PJ, Pokharel K. Severe cisplatin-induced renal toxicity in a
patient with xeroderma pigmentosum. J Oncol Pharm Pract. 2022 Mar
1;28(2):466–70.
12. Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, et al.
Xeroderma pigmentosum group D haplotype predicts for response, survival,
and toxicity after platinum-based chemotherapy in advanced nonsmall cell
lung cancer: XPD Haplotype and Lung Cancer. Cancer. 2006 Jun
1;106(11):2421–7.
13. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of
cisplatin–DNA adducts by the mammalian excision nuclease.
Biochemistry. 1996 Aug 6;35(31):10004–13.
14. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity
associated with platinating agents. Cancer Treat Rev. 2007 Feb
1;33(1):9–23.
15. Hu LB, Chen Y, Meng XD, Yu P, He X, Li J. Nucleotide Excision Repair
Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of
Human Colorectal Cancer to Chemotherapy and Ionizing Radiation. Front
Oncol. 2018;8:290.
16. Fayyad N, Kobaisi F, Beal D, Mahfouf W, Ged C, Morice-Picard F, et
al. Xeroderma Pigmentosum C (XPC) Mutations in Primary Fibroblasts
Impair Base Excision Repair Pathway and Increase Oxidative DNA Damage.
Front Genet. 2020;11:561687.